Transgenic LRRK2R1441G rats - a model for Parkinson disease?

Komal T Shaikh, Alvin Yang, Ekaterina Youshin, Susanne Schmid

Parkinson disease (PD) is the most common movement disorder, characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra. While the cause of this disease is largely unknown, are rare autosomal dominant familial form of PD is caused by a genetic mutation in the leucine-rich repeat kinase 2 (LRRK2) gene that presumably leads to a gain-of-function of LRRK2 kinase activity. Here, we explored the potential of over expression of this human gene in a new transgenic rat model to serve as an animal model for PD. Commercially available BAC transgenic rats expressing human LRRK2 with the familial PD mutation, R1441G, and their wild-type siblings were tested for deficits in motor function, sensorimotor gating, and higher cognitive function reminiscent of PD through the ages of 3, 6, 9 and 12 months. At 12 months of age, rats were exposed to intraperitoneal injections of the environmental toxin Paraquat or saline. Our results indicate that LRRK2R1441G transgenic rats do not show signs of neurodegeneration and do not develop significant motor or cognitive deficits until the age of 16 months. In addition, LRRK2R1441G transgenic rats did not show increased vulnerability to sub-toxic doses of Paraquat. Gene expression studies indicate that despite genomic presence and initial expression of the transgene, its expression was greatly reduced in our aged rats. We conclude that the transgenic LRRK2R1441G rat is not a valid model for studying the pathology of PD and discuss this in relation to other transgenic rat models.
Transgenic LRRK2\textsuperscript{R1441G} rats - a model for Parkinson disease?

Komal Shaikh, Alvin Yang, Kate Youshin, Susanne Schmid

Anatomy & Cell Biology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada

#corresponding author: Dr. Susanne Schmid, Anatomy and Cell Biology, Schulich School of Medicine and Dentistry, Western University, London, ON, N6A 5C1

Tel: +1- 519- 661 2111 ext. 82668, Fax: +1- 519- 661 3936, email: susanne.schmid@schulich.uwo.ca
Abstract
Parkinson disease (PD) is the most common movement disorder, characterized by the progressive
degeneration of dopaminergic neurons in the substantia nigra. While the cause of this disease is largely
unknown, are rare autosomal dominant familial form of PD is caused by a genetic mutation in the
leucine-rich repeat kinase 2 (LRRK2) gene that presumably leads to a gain-of-function of LRRK2
kinase activity. Here, we explored the potential of over expression of this human gene in a new
transgenic rat model to serve as an animal model for PD. Commercially available BAC transgenic rats
expressing human LRRK2 with the familial PD mutation, R1441G, and their wild-type siblings were
tested for deficits in motor function, sensorimotor gating, and higher cognitive function reminiscent of
PD through the ages of 3, 6, 9 and 12 months. At 12 months of age, rats were exposed to
intraperitoneal injections of the environmental toxin Paraquat or saline. Our results indicate that
LRRK2 R1441G transgenic rats do not show signs of neurodegeneration and do not develop significant
motor or cognitive deficits until the age of 16 months. In addition, LRRK2 R1441G transgenic rats did not
show increased vulnerability to sub-toxic doses of Paraquat. Gene expression studies indicate that
despite genomic presence and initial expression of the transgene, its expression was greatly reduced in
our aged rats. We conclude that the transgenic LRRK2 R1441G rat is not a valid model for studying the
pathology of PD and discuss this in relation to other transgenic rat models.

Keywords
Parkinson disease, leucine-rich repeat kinase 2, genetic model, transgenic rat, motor testing, cognitive
function, Paraquat
Introduction

Parkinson disease (PD) is characterized by the degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) causing cardinal motor symptoms including resting tremor, rigidity, bradykinesia, and abnormal gait. These symptoms occur relatively late in the time course of the disease by the time when 60% of dopaminergic neurons have degenerated and striatal dopamine (DA) content has been reduced by 80% (Bernheimer et al., 1973). In addition, PD patients may present with cognitive symptoms, including depression, anxiety and impaired memory (Emre, 2003).

While most cases of PD are sporadic, 5-10% are associated with familial mutations, most commonly in the \textit{LRRK2} gene (Paisan-Ruiz et al., 2004; Zimprich et al., 2004). \textit{LRRK2} encodes leucine-rich-repeat kinase II, a large multidomain protein with both kinase and GTPase enzymatic functions (Zimprich et al., 2004; Santpere & Ferrer, 2009). In addition, LRRK2 has several functional motifs and has been implicated in a variety of cellular processes including mitochondrial function, signal transduction, cell death pathways, vesicle trafficking, neurite outgrowth, autophagy and cytoskeleton assembly (Santpere & Ferrer, 2009; Cookson et al., 2010; Berwick et al., 2011; Tsika & Moore, 2012). The R1441G mutation on \textit{LRRK2} decreases GTPase activity and might thereby increase kinase activity, however, the physiological function of LRRK2 and the regulation of its enzymatic activity is not fully understood (Healy et al., 2008; Tsika and Moore, 2013). It is the second most common mutation causing PD, with a progression that is indistinguishable from sporadic PD, suggesting similar underlying mechanisms.

Transgenic mouse models were developed to gain insight into the mechanisms through which familial \textit{LRRK2} mutations are linked to PD pathogenesis. Li and colleagues (2009) described a \textit{LRRK2^{R1441G}} BAC transgenic mouse line that recapitulates human PD phenotypes, including L-DOPA responsiveness and age dependent motor deficits starting at 6 months of age and progressively
worsening by 12 months of age. While these animals did not show dopaminergic neuron degeneration in the SNpc or aggregation of α-synuclein, dopamine release was impaired and axonal dystrophy reminiscent of PD was noted in the striatum. However, following studies with these mice have largely failed to reproduce the motor dysfunction, only mild Parkinsonism, gastrointestinal dysfunction, and impaired dopaminergic transmission were reported in some studies (Bichler et al., 2013; Dranka et al., 2013).

One explanation for the lack of full PD pathology in the transgenic mouse may be that multiple factors, such as interactions with other genes or environmental stressors are required to inhibit compensatory mechanisms and facilitate the degenerative process. The relatively low incidence of familial PD, failure to recapitulate PD phenotypes in genetic models, and lack of singular environmental insults causing PD, has prompted the emergence of the ‘multiple hit’ hypothesis of PD. It suggests that multiple risk factors interact to induce the degenerative process, with the primary insult causing cellular stress and all succeeding insults resulting in a loss of protective pathways which together lead to neuronal death (Sulzer, 2007). Exposure to environmental toxins, particularly agrochemicals, has been suggested as possible additional risk factor. In particular, exposure to \(N,N'\)-dimethyl-4-4′-bipyridinium dichloride, or Paraquat, has been shown to increase PD risk (Costello et al., 2009).

Paraquat, a widely used herbicide, induces PD related neuropathology presumably through increased oxidative stress and production of reactive oxygen species (ROS).

The aim of the present study was to determine if mutated \(LRRK2\) induces PD phenotypes in a new transgenic rat model, \(BAC LRRK2^{R1441G}\) rats, and how exposure to Paraquat influences the phenotype.

**Materials and Methods**

**Animals**
A commercially available breeding pair of Sprague Dawley rats expressing the R1441G mutation on the human gene \textit{LRRK2} was obtained from Taconic (NY, USA). According to the Taconic records and qRT-PCR results published on the Taconic website at the time of purchase, hemizygous rats expressed 5-10 copies of the transgene. The model was originally created by Dr. Chenjian Li, with support of the Michael J. Fox Foundation, through pronuclear injection of the human \textit{LRRK2}^{R1441G} gene into Sprague Dawley zygotes. Animals for this study were obtained through in house breeding of the purchased pair which was a hemizygous male and a wild-type SD female. Pubs were weaned at 3 weeks of age and genotyped to detect human \textit{LRRK2}. Transgenic animals were housed with wild-type littermates in a 12 h light-dark cycle with food and water provided ad libitum. All 17 wild-type and 24 \textit{LRRK2}^{R1441G} transgenic rats underwent the entire battery of behavioral tests unless otherwise noted. Animals underwent behavioral tests at 3 months, 6 months, 9 months and 12 months of age. All procedures were in accordance with the ethical guidelines of the Canadian Council on Animal Care (CCAC) and approved by the University of Western Ontario Animal Use Subcommittee, protocol no. 2011-077.

**Genotyping**

Before weaning, all rats were genotyped by polymerase chain reaction (PCR) using tissue obtained from ear-punching. Genotyping was performed using an assay kit from Taconic according to their specifications. The PCR reaction combined 5 µL of genomic DNA (2 ng/µL), 2.5 µL of PCR Buffer (5 mM), 1 µL of MgCl$_2$ (2.5 mM), 0.5 µL of deoxynucleotide mixture (0.2 mM), 0.5 µL of hpark8-F primer (0.5µM), 0.5 µL of hpark8-R primer (0.5µM) and 0.25 µL of HotStarTaq DNA Polymerase (0.05U/µL). The thermocycler protocol involved 15 min at 95°C, 35 cycles with 45 s at 94°C, 1 min at 65°C, and 1 min at 72°C, and 5 min. extension at 72°C. The primer sequence for the hpark8-F primer was GAT AGG CGG CTT TCA TTT TTC C and for the hpark8-R primer ACT CAG GCC CCA AAA
ACG AG. Primers were generated in house at the UWO Oligo factory (see supplementary figure S1).

All rats were genotyped for a second time post-mortem.

Behavioral Testing

All 17 wild-type and 24 $LRRK^{2R1441G}$ transgenic rats underwent the entire battery of behavioral tests at the different age stages unless otherwise noted. Tests were always performed in the same order and on separate days.

**Vibrissae-evoked forelimb placing:** The forelimb placing test was performed as previously described and used as a measure of movement initiation abilities (Woodlee et al., 2005), a common deficit observed in PD patients. Briefly, the experimenter holds the animal aloft by its torso and brushes its vibrissae against the edge of the testing surface. This elicits a forelimb placing response from the limb on the same side. Placing is quantified as the percentage of correct responses or ‘hits’ elicited out of fifteen trials. Trials in which the animal struggles or resists the experimenter’s grip are discounted. Animals were all trained on this task prior to testing in order to ensure acclimation to the experimenter as well as reduction in struggling behaviors.

**Adjusting steps:** The adjusting steps task has been extensively used to measure postural stability in rats (Olsson et al., 1995, Chang et al., 1999, Fleming et al., 2009). The experimenter holds the animal by its torso such that its hindlimbs are lifted above the testing surface. One forelimb is then restrained so that the animal’s weight is entirely supported by the remaining free forelimb, which is in contact with the testing surface. The experimenter then moves the animal laterally across a testing surface with a distance of 70 cm. In order to compensate for the movement of the body, the animal should make adjusting steps with the weight-bearing forelimb. The average number of steps each animal makes over
five trials is recorded and used for analysis. Animals with nigrostriatal degeneration will drag their forelimb instead of making the appropriate adjusting steps (Fleming et al., 2012).

Footprint Analysis: Footprint analysis was performed in order to assess stepping patterns and abnormal gait (Li et al., 2010). The rat’s paws were dipped in non-toxic paint and it was placed on a runway 110 cm long, 10 cm wide and with 25 cm high side walls. The runway led to the rat’s home cage and rats were thus motivated to traverse the gangway. The floor of the runway was lined with ordinary paper and the footprints marked on the paper were analyzed. The distance between forepaws and the left and right stride were recorded.

Open Field Test: The open field test was used to measure general locomotor activity in wild-type and transgenic rats. Each animal was placed in a square activity box (Med Associates Activity Monitor, St. Albans, VT, USA) for 30 minutes per day, for two days. Horizontal and vertical movements were detected by two rows of photo beams. After each animal finished testing, the activity boxes were cleaned with 70% ethanol to eliminate any odors which may bias the next animal. Using the MedAssociates Activity Monitor software, we analyzed the distance traveled and the number of rearing movements during the testing interval. Exploratory rearing was used as an indirect measure of paucity of movement, as previously shown (Landers et al., 2014)

Acoustic Startle Response and Sensorimotor Gating Test: The acoustic startle response of these animals was tested using a protocol similar to those previously described (Valsamis & Schmid, 2011; Typlt et al., 2013). Startle testing was conducted in sound attenuated startle boxes from Med Associates (MED ASR PRO1, St Albans, VT, USA). Animals were placed in holders mounted on a movement sensitive platform within the startle box. A transducer converted the vertical movement of the platform, induced by the animal’s startle response, into a voltage signal. The maximum amplitude of the signal was measured using Med Associates software (Startle Reflex Version 6, Med Associates,
St Albans, VT, USA). On day 1, animals were acclimated to the startle box and background noise (65 dB white noise) for 5 minutes in the morning and again for 5 minutes several hours later. On day 2, animals underwent an input-output (IO) test to determine the appropriate gain setting for each animal. The IO function has an initial stimulation at 65 dB (20 ms duration) and increased in 5 dB intervals to 120 dB. On day 3, animals were tested in two blocks for short term habituation and prepulse inhibition respectively. Block 1 assessed habituation by presenting 30 trials of the startle pulse (105 dB white noise, 20 ms duration and 15 ms intertrial interval). Block 2 assessed prepulse inhibition. In Block 2, there were seven different trial conditions (10 trials per condition) for a total of 70 trials. The trials presented the startle pulse alone, a low prepulse of 75 dB (4 ms duration) before the startle pulse, and a high prepulse of 85 dB (4 ms duration) before the startle pulse. The presentation of the prepulse and the startling pulse was separated by three different interstimulus intervals (ISIs): 10 ms, 30 ms or 100 ms. The trials were presented in pseudorandomized order. Animals were tested on both habituation and prepulse inhibition as both responses are disrupted in PD patients (Matsumoto et al., 1992; Zoetmulder et al., 2014).

Morris Water Maze: Both wild-type and transgenic animals underwent two versions of the Morris water maze task to assess learning and memory. The first was a cued version that heavily relies on striatal function, the second was the classical spatial version that tests hippocampal function. The task was conducted in a round tank, 146 cm in diameter and 58 cm deep (Stoelting Co., Wood Dale, IL, USA), filled with water. The water was colored with non-toxic blue paint to ensure opaqueness. Throughout testing, the water temperature was monitored and maintained at 21°C. The tank was divided into four equally sized quadrants and a circular acrylic escape platform was placed in one of the quadrants. The escape platform was submerged in water by 2 cm so that it was not visible to the animals. A camera mounted above the tank recorded the movement of the animals in each trial. The
Any-maze Behavior Tracking Software (Stoelting Co., Wood Dale, IL, USA) was used to record the latency to reach the escape platform and the time spent in the target quadrant.

All animals were first tested on the cued version of the water maze task. This consisted of two training days with four trials on each day. In each trial, the animals were placed in the water facing the tank wall and had to locate the escape platform, which was cued by a yellow ball attached to the platform and protruding from the water. The trial was completed when the animal either found the escape platform or 90 s had passed. If the animal was unable to locate the platform in 90 s, it was gently led to the platform. Animals were allowed to remain on the escape platform for 15 s before being removed and dried before the next trial. The initial position of the animal was the vertices of one of the four quadrants and was different for each trial. The initial position was assigned randomly and counterbalanced for the genotypes. The platform position was also changed between each trial and was randomly assigned and counterbalanced.

The animals were also tested on the spatial reference version of the water maze as previously described (Miyoshi et al., 2002). This consisted of four training days with four trials on each day. The experimental procedure was similar to the previous one, except that the location of the platform was no longer cued. Instead, animals could utilize external visual cues on the walls surrounding the tank to locate the platform. In addition, the platform position was kept constant between trials and days. The first four trials of the first of the four training days were used as an indicator of spatial working memory.

On day 7, experimenters ran a 90 s probe trial without the platform. During this trial, the time spent in the target quadrant was recorded for each animal.
Paraquat Injections

All animals that reached the age of 12 months were exposed to an acute sub-toxic Paraquat regimen at the age of 12 months, as previously described by Hutson et al. (2011), in order to assess their vulnerability to the environmental toxin. Animals were separated into four groups: wild-type/saline, wild-type/Paraquat, transgenic/saline, and transgenic/Paraquat. Within the genotypes, animals were randomly assigned to saline versus paraquat groups. Animals received two IP injections of Paraquat (10 mg/kg dissolved in 0.9% saline) or saline, with three days in between injections. At the time of last behavioural testing, animals were 14-18 months old. The toxin dose used in this study was a quarter of that previously shown to cause dopaminergic cell death in the substantia nigra in adult rats (Cicchetti et al., 2005). All animals underwent the open field test (for detailed description see above) immediately after receiving injections and 24 hours after injections. As previously mentioned, MedAssociates Activity Monitor software was used to analyze the number of rearing movements during a 30 minute testing interval.

Histology

One wild-type and one LRRK2R1441G rat of 3 months, 6 months, and 9 months of age and two rats per genotype of 18 months of age were used for histological analysis. Rats were deeply anaesthetized with sodium pentobarbital (54.7 mg/kg body weight; Comparative Medicine Animal Resources Center, Montreal, ON, Canada) and perfused transcardially with 0.9% saline solution at room temperature, followed by 0.1 M phosphate buffered saline (PBS; pH7.4) containing 4% paraformaldehyde (PFA) at 4°C. Brains were then fixed in 4% PFA for 1 hour and placed in 30% sucrose phosphate buffer (PB) at 4°C until needed. Brain sections (40µm thickness) containing the substantia nigra were cut. Free-floating brain sections were blocked in 1% H2O2 (30% stock solution) in 0.1M PBS (pH7.35), followed
by treatment with PBS+ (0.4% Triton-X and 0.1% BSA) for one hour. Sections were incubated with mouse anti-TH (1:8000) or rabbit anti-DAT (1:250, both Millipore CA, USA) in PBS+ overnight.

Next, sections were rinsed using PBS and incubated with biotinylated goat-anti-mouse or goat-anti-rabbit secondary antibodies in PBS+ (1:500; from Vector Laboratories Inc., Burlingame, CA, USA) for one hour. Thereafter, sections were rinsed with PBS, incubated with Avidin/Biotin Complex (1:1000; Vector Laboratories Inc., Burlingame, CA, USA) for one hour; rinsed and then stained with 3-3’-diaminobenzidine (Sigma-Aldrich) in 0.1M PB with 0.0004% H$_2$O$_2$. All incubations were done at room temperature. Sections were then rinsed with PB and mounted using 0.3% Gelatin A, and air-dried. Some TH sections were processed for Nissl counterstaining using a standard protocol, and cover slipped using Entellan mounting medium (EM Science, Gibbstown, NJ, USA). For Hoechst 33342 staining, free-floating brain sections were treated with Thermo Scientific Hoechst 33342 fluorescent stain according to (Thermo Fisher Scientific, Waltham, MA, USA), rinsed with PBS and mounted using 0.3% Gelatin A and air-dried. Slides were cover slipped using Vectashield (Vector Laboratories Inc., Burlingame, CA, USA). TH stained sections were examined using a Zeiss Axioplan microscope and pictures were taken at 2.5X magnification for quantification. Hoechst stained cells were counted under 63Xs magnification. For each brain area of interest, 3 sections per animal were matched between wild-type and experimental cohorts for examination and calculation of averages. Cells stained for TH were quantified using ImageJ. Section images were adjusted to 8-bit black and white and threshold was set to white=0 and black=225. The mean grey value was obtained to indicate the level of staining per section. Section labels were coded and covered during analysis so that the experimenter was blinded to the experimental group, in order to prevent group bias. All sections were analyzed by two persons independently.
Surviving transgenic rats were perfused after the Paraquat study with saline and samples for various brain regions (cortex, substantia nigra, hippocampus) as well as liver and kidney were obtained and frozen on ice. RNA was isolated using QIAzol Lysis Reagent (Qiagen, Germantown, MD, CA) according to the manufacturer’s instructions. cDNA was synthesized using Life Technologies high-capacity cDNA Reverse Transcription Kit (Life Technologies, Grand Island, NY, USA). Real time PCR assays were performed in triplicate on a 384 well plate. The level of human LRRK2 mRNA was detected using TaqMan probe Hs00411197_ml specific for human LRRK2 (Life Technologies, Grand Island, NY, USA). The housekeeping gene GAPDH was detected using Rn01775763 (Life Technologies, Grand Island, NY, USA) and was used as a reference gene.

Statistical Analysis

Mean values ± standard error are reported. Outliers, defined as data points three standard deviations from the mean, were identified and removed from the data set. Comparisons of genotype and treatment groups were performed using repeated measures ANOVA. The Huynh-Feldt correction was used when sphericity was violated in behavioural experiments and epsilon was greater than 0.75. When sphericity was violated but epsilon was lower than 0.75, the more conservative Greenhouse-Geisser correction was used to adjust the degrees of freedom. IBM SPSS Statistics 2.0 software was used for all statistical analyses. Results were considered statistically significant at a p value of 0.05.

Results
All animals were weighed before behavioral testing, at each age point. All rats significantly increased their weight over time \([\text{ANOVA } F(2,75)=378.90, p<0.001, \text{ Greenhouse-Geisser correction}]\), however there was no significant difference in weight between transgenic \(\text{LRRK2}^{R1441G}\) rats and their wild-type littermates \([\text{ANOVA } F(2,75)=0.63, p=0.52, \text{ Greenhouse-Geisser correction; data not shown}]\).

**Motor Tests**

In order to assess movement initiation abilities, vibrissae-evoked forelimb placing responses were measured in transgenic \(\text{LRRK2}^{R1441G}\) rats and their wild-type littermates at 3, 6, 9 and 12 months of age. While a significant main effect of age was noted in forelimb placing responses \([\text{ANOVA } F(2,85)=8.14, p <0.05, \text{ Huynh-Feldt correction}]\), no genotype and age interaction was noted \([\text{ANOVA } F(2,85)=0.37, p=0.71, \text{ Huynh-Feldt correction}]\). Therefore, transgenic \(\text{LRRK2}^{R1441G}\) did not significantly differ from wild-type rats in vibrissae-evoked forelimb placing, suggesting intact movement initiation abilities (Figure 1A).

Postural stability in was measured using the adjusting steps task. While a small but significant main effect of age was noted in the number of adjusting steps made \([\text{ANOVA } F(3,102)=3.40, p <0.05, \text{ Huynh-Feldt correction}]\), no genotype and age interaction was noted \([\text{ANOVA } F(3,102)=1.06, p=0.37, \text{ Huynh-Feldt correction}]\). Transgenic \(\text{LRRK2}^{R1441G}\) rats did not significantly differ from wild-type rats in the adjusting steps task, suggesting normal postural stability (Figure 1B).

Foot print analysis was conducted on all animals in order to assess gait patterns. A main effect of age was noted in stride length of animals \([\text{ANOVA } F(3,105)=37.36, p <0.05, \text{ Huynh-Feldt correction}]\). Both right and left stride lengths were measured in all animals, however, no main effect of side was noted \([\text{ANOVA } F(1,39)=0.12, p=0.72, \text{ Huynh-Feldt correction}]\). In addition, there was no interaction
between age, side and genotype [ANOVA $F(3,117)=0.60$, $p=0.62$, Huynh-Feldt correction]. Therefore $LRRK2^{R1441G}$ rats showed normal gait patterns compared to wild-type controls (Figure 1C).

Lastly, general locomotor activity of transgenic $LRRK2^{R1441G}$ rats and wild-type controls was assessed in the open field test. Animals were tested for two 30 minute sessions across two consecutive days. Data presented here is calculated across both sessions. There was no significant difference between transgenic and wild-type animals in the total distance travelled during the two sessions [ANOVA $F(3,102)=0.47$, $p=0.67$, Huynh-Feldt correction.], although a main effect of age group was noted [ANOVA $F(3,102)=29.71$, $p<0.001$, Huynh-Feldt correction; Figure 1D]. Overall, it seems as rats became familiar with the testing boxes due to repeated exposure, exploratory locomotor behavior decreased. Similarly, no significant difference in rearing behavior was noted between transgenic and wild-type rats [ANOVA $F(3,103)=0.79$, $p=0.49$, Huynh-Feldt correction], although an effect of age stage was noted [ANOVA $F(3,102)=19.33$, $p<0.001$, Huynh-Feldt correction; Figure 1E]. The number of rearings dropped significantly in animals of 12 months of age. Finally, there was no difference in maximal velocity of transgenic $LRRK2^{R1441G}$ rats and wild-type controls in the locomotor boxes [ANOVA $F(3,117)=0.59$, $p=0.62$; Figure 1F].

In summary, while many motor tests showed general effects of age and/or repeated testing, there were no signs of any motor impairment in $LRRK2^{R1441G}$ rats up to the age of 1 year.

Sensorimotor Gating Tests

The acoustic startle response was used to investigate sensorimotor gating mechanisms, including habituation and prepulse inhibition. Baseline startle amplitude was calculated from the average of the first two startle responses of testing at each age stage and was not significantly different between
transgenic and wild-type rats or between age stages [ANOVA \( F(2,103) = 0.32, \ p = 0.79 \), Huynh-Feldt correction; data not shown]. Habituation scores were calculated by dividing the average of the startle responses of trials number 25-30 by the maximum of the first three startle responses. Habituation scores of transgenic \( LRRK2^{R1441G} \) rats and wild-type littermates did not significantly differ [ANOVA \( F(3,102) = 0.33, \ p = 0.78 \), Huynh-Feldt correction; Figure 2A]. The time course of habituation was also assessed by examining the attenuation of startle response over the entire 30 trials using repeated measures ANOVA. At 3 months of age, a significant decrease in startle amplitude was noted [ANOVA \( F(16,643) = 3.29, \ p < 0.001 \), Huynh-Feldt correction], however there was no significant difference between transgenic and wild-type rats [ANOVA \( F(16, 643) = 0.68, \ p = 0.82 \), Huynh-Feldt correction; Figure 2B top]. Similarly, significant habituation was observed in all animals at 6 [ANOVA \( F(12,476) = 2.85, \ p < 0.001 \), Huynh-Feldt correction], 9 [ANOVA \( F(16,640) = 1.91, \ p < 0.05 \), Huynh-Feldt correction] and 12 months of age [ANOVA \( F(16,637) = 2.97, \ p < 0.001 \), Huynh-Feldt correction; Figure 2B bottom], but no significant difference between the genotypes was observed [6 months ANOVA \( F(12,476) = 0.78, \ p = 0.67 \), Huynh-Feldt correction; 9 months ANOVA \( F(16,640) = 1.04, \ p = 0.42 \), Huynh-Feldt correction; 12 months ANOVA \( F(16,637) = 0.92, \ p = 0.55 \), Huynh-Feldt correction].

Prepulse inhibition was measured using two different prepulse levels (75 dB and 85 dB) and three different interstimulus intervals (10 ms, 30 ms, 100 ms). At 3 months, a significant main effect of prepulse [ANOVA \( F(1,39) = 32.10, \ p < 0.001 \)] and ISI was noted [ANOVA \( F(2,78) = 10.28, \ p < 0.001 \)], however there was no significant difference between transgenic and wild-type rats [ANOVA \( F(2,78) = 0.64, \ p = 0.53 \), Figure 2C top]. Therefore at 3 months of age, all rats displayed prepulse inhibition, with no significant difference between the two genotypes. Similarly, prepulse inhibition was noted at 6 months [ANOVA \( F(1,39) = 61.53, \ p < 0.001 \), Huynh-Feldt correction; data not shown], 9
months [ANOVA \(F(1,39)=30.40, \ p<0.001\), Huynh-Feldt correction; data not shown], and 12 months of age [ANOVA \(F(1,39)=29.83, \ p<0.001\), Huynh-Feldt correction; Figure 2C bottom], however there was no difference in the extent of inhibition between transgenic \(LRRK2^{R1441G}\) rats and wild-type controls [6 months ANOVA \(F(2,61)=0.228, \ p=0.74\), Huynh-Feldt correction; 9 months ANOVA \(F(2,78)=1.49, \ p=0.23\), Huynh-Feldt correction; 12 months ANOVA \(F(2,78)=1.59, \ p=0.21\), Huynh-Feldt correction].

In summary, \(LRRK2^{R1441G}\) rats showed no signs of sensorimotor gating deficits at any age stage.

**Morris Water Maze**

At older age stages of 9 and 12 months, all rats were additionally tested on the Morris water maze in order to assess spatial learning. In the cued version of the test, latency to find the escape platform improved over training days at 9 months [ANOVA \(F(1,39)=31.73, \ p<0.001\), Huynh-Feldt correction, Fig. 3A top] and 12 months of age [ANOVA \(F(1,38)=7.11, \ p<0.05\), Huynh-Feldt correction, 3A bottom]. However, at both 9 months [ANOVA \(F(1,39)=0.06, \ p=0.81\), Huynh-Feldt correction] and 12 months [ANOVA \(F(1,38)=1.54, \ p=0.22\), Huynh-Feldt correction], there was no significant difference between transgenic \(LRRK2^{R1441G}\) rats and wild-type controls (Figure 3A).

In the spatial version of the test, training improved the mean latency to the platform in all rats at 9 months [ANOVA \(F(2,66)=13.6, \ p<0.001\), Huynh-Feldt correction, Fig. 3B top] and 12 months of age [ANOVA \(F(3,102)=15.34, \ p<0.001\), Huynh-Feldt correction, Fig. 3B bottom], however no significant genotype difference was noted at either age point [9 months: ANOVA \(F(2, 66)=0.93, \ p=0.39\), Huynh-Feldt correction; 12 months: ANOVA \(F(3,102)=1.09, \ p=0.35\), Huynh-Feldt correction; Figure 3B].
In the working memory analysis of the test (first 4 trials of the first training day), performance improved as a function of trials at 9 months [ANOVA $F(2,91)=9.7, p<0.001$, Huynh-Feldt correction, Fig. 3C top] and 12 months of age [ANOVA $F(2,68)=3.72, p<0.05$, Huynh-Feldt correction, Fig. 3C bottom]. Again, there was no significant difference between transgenic and wild-type animals at 9 months [ANOVA $F(2, 91)=1.10, p=0.34$, Huynh-Feldt correction] and 12 months of age [ANOVA $F(2, 68)=1.15, p=0.32$, Huynh-Feldt correction; Figure 3C].

Finally, a probe trial was conducted at the end of testing to assess the amount of time spent in the target quadrant. At 9 months [$t(39)=0.43, p=0.67$; Figure 3D top] and 12 months of age [$t(38)=0.30, p=0.77$; Figure 3D bottom] there was no significant difference in time spent in target quadrant between transgenic LRRK2$^{R1441G}$ rats and their wild-type littermates (Figure 3D).

In summary, there were no cognitive deficits detectable in LRRK2$^{R1441G}$ rats with the Morris water maze.

### Paraquat Vulnerability in aged LRRK2$^{R1441G}$ transgenic rats

In order to assess gene environment interactions in PD, vulnerability to Paraquat was tested in aged LRRK2$^{R1441G}$ transgenic rats at approximately 14-16 months of age. Transgenic and wild-type rats were exposed to acute Paraquat at a subtoxic dose and rearing behavior was recorded. Animals received two injections of Paraquat (n= 8 wild-type and 11 LRRK2$^{R1441G}$) or saline (n= 8 wild-type and 10 LRRK2$^{R1441G}$) and rearing behavior was measured immediately after each injection, 24 hours after each injection and ten days post injection (Figure 4). A significant reduction in rearing behavior over testing time points was noted in all animals [ANOVA $F(3, 83)=9.30, p<0.001$, Greenhouse-Geisser correction]. As expected, there was no overall main effect of drug, as a low dose of Paraquat was used in this experiment [ANOVA $F(3, 83)=2.50, p=0.83$, Greenhouse-Geisser correction]. There was no
interaction between time, drug and genotype [ANOVA $F(3, 83)=0.30, p=0.83$, Greenhouse-Geisser correction]. Therefore, \textit{LRRK2}^{R1441G} transgenic rats did not show increased vulnerability to Paraquat at the dose employed. In addition, univariate ANOVA analysis was conducted at each testing point. Immediately after injection 1, Paraquat exposed groups displayed significantly reduced rearing movements [ANOVA $F(1, 32)=5.51, p<0.05$], however the transgenic animals did not significantly differ from wild-type controls [ANOVA $F(1, 32)=0.033, p=0.857$]. This effect was lost 24 hours post injection 1, and no significant difference in rearing behavior was noted between groups exposed to Paraquat or saline [ANOVA $F(1, 28)=1.81, p=0.189$]. Immediately following injection 2, again, a significant main effect of drug was again noted [ANOVA $F(1, 28)=8.45, p<0.05$], but no significant difference between transgenic and wild-type controls [ANOVA $F(1, 28)=0.23, p=0.64$]. 24 hours later, there was no difference between groups exposed to Paraquat or saline [ANOVA $F(1, 28)=2.73, p=0.06$]. Ten days post injection two, there was also no significant main effect of drug [ANOVA $F(1, 28)=1.10, p=0.30$] or genotype and drug interaction [ANOVA $F(1, 28)=0.37, p=0.55$].

In summary, Paraquat had a short term effect on rearing behavior immediately following injections, but this effect was not selective for \textit{LRRK2}^{R1441G} rats, and was not detectable ten days post injection.

\textit{Animal survival}

As animals aged beyond the 12 month time point, and specifically during the Paraquat testing, 2 wt animals and 10 transgenic \textit{LRRK2}^{R1441G} rat spontaneously died. Kaplan-Meier curves and a log rank (Mantel-Cox) test were conducted to investigate survival estimates in transgenic \textit{LRRK2}^{R1441G} and wild-type rats until all surviving animals were sacrificed to harvest tissue for qRT-PCR (Figure 5). While there was no statistical significant difference in survival time between transgenic and wild-type animals up to that point [$X^2(1)=2.65, p=0.10$], it might have become apparent if animals would have been allowed to survive for a longer time period. We chose to sacrifice the remaining animals at 18
months of age in order to ensure that we can harvest tissue for quantitative RT-PCR analysis of gene
expression levels. Interestingly, post mortem analysis of rats that did not survive revealed different
hemopoietic tumors in all transgenic animals, but only one wild-type animal as probable cause of
death.

**Histology and qRT-PCR**

In order to assess potential neuro-degeneration in the substantia nigra, we performed immunostaining
of dopaminergic neurons using a tyrosine hydroxylase antibody (Figure 6A), and of cell nuclei using
Hoechst 33342 staining at age stages of 3, 6, and 18 months (Figure 6B). Stereological quantification
of TH staining revealed no significant age and genotype interaction in the amount of staining in the
substantia nigra \[ANOVA F(2, 2)=0.022, p=0.979; Figure 6C\]. Analysis of the Hoechst 33342 stain
revealed no differences in the number of stained nuclei in the substantia nigra, nor an apparent
condensation or fragmentation of nuclei at the older age stage that would indicate a higher level of
apoptosis \[ANOVA F(1, 2)=0.00, p=1.00; Figure 6D\].

Additionally, we quantified staining for tyrosine hydroxylase (TH) in the dorsal striatum, the main
termination area of dopaminergic projections from the substantia nigra (Fig. 7a). We found no
difference in DAT expression between genotypes \(p=0.864\), age groups \(p=0.258\), or interactions of
genotype and age group \[ANOVA F(2, 2)=0.022, p=0.997; Figure 7B\]. We also quantified the
expression of the dopamine transporter (DAT) in the dorsal striatum. ANOVA revealed a significant
effect of age group on DAT expression \[ANOVA F(2, 2)=21, p=0.048; Figure 7C and D\], but no
effect of genotype or interaction of genotype with age group.

Initial qRT-PCR results have indicated an expression of 8-10 copies of the transgene in these rats, and
genotyping of rats tested here had confirmed a genomic presence of human *LRRK2* in all transgenic
animals (see Figure S1). We sacrificed the 13 surviving transgenic rats at the end of our study in order
to repeat qRT-PCR analysis of gene expression. The results revealed a low expression of human
*LRRK2* in the substantia nigra, cortex, hippocampus, liver or kidney, that was below detection level
(see table 1), indicating that the gene expression levels had been down regulated in the surviving
animals.

Discussion

Animal models are critical tools for not only understanding LRRK2 pathology, but PD aetiology and
pathogenesis. In particular, models which carry PD related mutations on the human *LRRK2* gene can
provide insight into LRRK2 function and the mechanisms by which it mediates PD related dysfunction.
Recently, bacterial artificial chromosome (BAC) *LRRK2* transgenic rodent models have been generated
which potentially allow for investigating the link between genetic mutations and development of PD.
Here we have characterized newly available transgenic *LRRK2*<sup>R1441G</sup> BAC rats. Unfortunately, these
rats do not display PD related motor or cognitive deficits by 12 months of age, nor do they show
increased vulnerability to Paraquat exposure as compared to age-matched wild-type controls.
An important limitation of the use of these animals is that there were no more detectable levels of
transgene expression in the aged *LRRK2*<sup>R1441G</sup> transgenic rats that survived until the end of study.
While all transgenic rats did display genomic human *LRRK2*<sup>R1441G</sup> in genotyping PCR results, this
gene seems to have become silenced at least in the surviving animals despite the fact that a BAC
approach was used. BAC constructs are large genomic inserts and due to their size (~200 kb) allow the
inclusion of endogenous regulatory elements. However the loss of transgene expression noted in this
model suggests that transgene insertion, even with the BAC approach, was not stable. It is a general
limitation of the transgenic approach that - due to random integration of the transgene - positional
effects can occur. Position effects refer to the phenomenon whereby transgene expression is influenced
by the site of integration. Position effects can include lack of transgene expression and extinction of transgene expression in successive generations.

Accordingly, post-mortem analysis conducted on rats which did not survive until the end of our study showed pathological morphologies consistent with hemopoietic tumors in $LRRK2^{R1441G}$. A recent study by Ruiz-Martinez et al (2014) reported a higher prevalence of hematological cancers in patients carrying the $LRRK2^{R1441G}$ mutation. The slightly higher mortality and the occurrence of hemopoietic tumors in all transgenic rats that died before the end of our study indicate that gene silencing might not have happened in all animals to the same extend.

Although to our knowledge no previous studies have examined PD phenotypes in $LRRK2^{R1441G}$ transgenic BAC rats, our results are consistent with a recent study where transgenic $LRRK2$ BAC mice failed to consistently reproduce cardinal features of PD. Although Li et al. (2009) originally reported age-dependent, L-DOPA responsive, progressive motor dysfunction in $LRRK2^{R1441G}$ BAC mice by 10 months of age, subsequent studies in transgenic mice have been unable to reproduce these results. Bichler et al. (2013) did not observe gross motor dysfunction in transgenic $LRRK2^{R1441G}$ BAC mice by 10 months of age, although modest motor deficits were observed in advanced age (21 months of age). These mice also did not display cognitive symptoms of PD, including depression and anxiety-like behaviour and impaired learning and memory (Bichler et al., 2013). However, gastrointestinal dysfunction, a common early non-motor symptom of PD was noted in these mice by 6 months of age (Bichler et al., 2013). Dranka et al. (2013) did not report gross motor abnormalities in $LRRK2^{R1441G}$ BAC mice, although by 16 months of age, these mice did display some deficits in motor coordination, an early symptom of PD. Similarly, other classic transgenic $LRRK2$ mouse models over-expressing mutant $LRRK2$ have mostly failed to show PD specific gross motor deficits (Li et al., 2009, 2010; Melrose et al., 2010) despite mild nigral neurodegeneration (Ramonet et al., 2011). An interesting approach was pursued by Tong and colleagues (2009) who created a $LRRK2$ R1441C knock-in mouse,
474 which is a model most closely mimicking the human PD situation without LRRK2 overexpression.
475 These mice did also not show any PD symptoms or nigrostriatal degeneration, but they had altered DA
476 transmission that became evident upon injection of amphetamine or the D2 receptor agonist quinpirole.
477 This impairment in stimulated dopamine transmission was suggested to be a pathogenic precursor
478 preseding neurodegeneration in PD brains.

479

480 Rodents as PD models
481 Parkinson disease is characterized by slow and progressive degeneration of the substantia nigra and
482 disruption of basal ganglia circuitry with advancing age. While neurotoxin models which display
483 disease outcomes have had some success, the progressive nature of the disease calls for a genetic
484 model with a progressive phenotype. The relatively short life span of rodents as compared to humans,
485 however, may make them imperfect models for studying genetic forms of PD. A healthy laboratory rat
486 can survive for maximally 2-3 years while LRRK2 mediated PD is not apparent in humans until after
487 65 years of age. Indeed, despite the discovery of many genetic mutations, the greatest known risk
488 factor for PD continues to be advanced age. The rats used in this study were up to 12 -16 months of
489 age, which is considered ‘advanced’ age for rats (Quinn, 2005), but this may not have been sufficient
490 to reproduce PD related phenotypes, even if some of them may have expressed the transgene to a
491 considerable extend. Some researchers have argued that extremely high levels of transgene expression
492 can induce neurological phenotypes within the life span of a rodent. Ramonet et al. (2011) tested four
493 different transgenic mouse lines, expressing either the G2019S mutation or the R1441C mutation and
494 observed neuronal loss in advanced age in only one line, in which transgene expression was more than
495 300% greater than the level of endogenous LRRK2. However, in this case non-physiological levels of
496 transgene expression are used which, while producing PD phenotypes, may limit our ability to translate
497 animal research to human disease.
In addition, the transgene is constitutively expressed in most rodent models, including our rats, so they were able to develop compensatory mechanisms which potentially counteracted the toxic effects of mutated LRRK2. While LRRK2 mutations in familiar PD are constitutively expressed as well, the over-expression of mutated LRRK2 might trigger the compensatory effects. Zhou et al (2011) found no behavioural phenotypes in rats that constitutively expressed mutated LRRK2\(^{G2019S}\) despite high gene expression, however, they did observe abnormal motor activity in rats with conditional adult onset expression of mutated LRRK2\(^{G2019S}\). Their results suggest that rats are able to accommodate LRRK2’s toxic effects when it is constitutively expressed. With this in mind, it might be more favourable to consider a conditional transgenic animal model and/or a viral mediated gene transfer approach instead of the BAC approach. With the viral mediated gene transfer approach, the mutated LRRK2 gene can be delivered to rodents through a viral vector in adulthood, thus bypassing the development of compensatory effects. This approach also allows researchers to target specific neuronal populations, such as susbtantia nigra dopaminergic neurons, to better model the degeneration seen in PD. Another advantage of the viral mediated gene transfer approach is that it allows researchers to correlate transgene dosage (by modulating copy number of transgene) with phenotype severity. Studies using this approach have already had success in recapitulating cardinal features of PD. Lee et al (2010) created a mouse model of PD expressing human LRRK2\(^{G2019S}\) using herpes simplex virus (HSV), which displayed 50% degeneration of nigral dopaminergic neurons. In addition a rat model generated by Dusonchet et al (2011) expressing human LRRK2\(^{G2019S}\) showed a 20% reduction in dopaminergic neurons. Tsika et al. (2014) developed conditional transgenic mice that selectively express human LRRK2\(^{R1441C}\) in dopaminergic neurons from the endogenous murine ROSA26 promoter. The animals showed no neurodegeneration or locomotor symptoms, but altered dendritic and nuclear morphology in dopaminergic neurons upon aging, indicating the onset of pathogenic processes. While the viral overexpression of mutated LRRK2 also has its clear limitations due to the non-physiological doses of
LRRK2, viral models may allow us to recapitulate some of the neurodegeneration processes observed in PD patients, which has so far been difficult to show in other models.

In summary, we here characterized transgenic BAC rats carrying the human LRRK2^{R1441G} mutation in terms of motor function, sensorimotor gating, cognitive function and dopaminergic cell loss in the substantia nigra. Transgenic LRRK2^{R1441G} rats did not stably express the transgene to a satisfactory extend, they didn’t display any symptoms reminiscent of Parkinson disease by 12 months of age, and they did not show increased vulnerability to the environmental toxin Paraquat. Overall, our results indicate that these transgenic BAC LRRK2^{R1441G} rats are not a viable model of Parkinson disease.

Acknowledgements:

This study was supported by the Canadian Institute for Health Research (CIHR) and the Canadian Foundation for Innovation (CFI), Leaders of Excellent Funds.

References

1. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of parkinson and huntington. clinical, morphological and neurochemical correlations. J Neurol Sci. 1973 Dec;20(4):415-55.
2. Berwick DC, Harvey K. LRRK2 signaling pathways: The key to unlocking neurodegeneration? Trends Cell Biol. 2011 May;21(5):257-65.
3. Bichler Z, Lim HC, Zeng L, Tan EK. Non-motor and motor features in LRRK2 transgenic mice. PLoS One. 2013 Jul 30;8(7):e70249.
4. Chang JW, Wachtel SR, Young D, Kang UJ. Biochemical and anatomical characterization of forepaw adjusting steps in rat models of parkinson's disease: Studies on medial forebrain bundle and striatal lesions. Neuroscience. 1999 Jan;88(2):617-28.
5. Cicchetti F, Lapointe N, Roberge-Tremblay A, Saint-Pierre M, Jimenez L, Ficke BW, Gross RE. Systemic exposure to paraquat and maneb models early Parkinson's disease in young adult rats. Neurobiol Dis. 2005 Nov;20(2):360-71.
6. Cookson MR. The role of leucine-rich repeat kinase 2 (LRRK2) in parkinson's disease. Nat Rev Neurosci. 2010 Dec;11(12):791-7.
7. Costello S, Cockburn M, Bronstein J, Zhang X, Ritz B. Parkinson's disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of california. Am J Epidemiol. 2009 Apr 15, 2009;169(8):919-26.

8. Dranka BP, Gifford A, Ghosh A, Zielonka J, Joseph J, Kanthasamy AG, Kalyanaraman B. Diapocynin prevents early parkinson's disease symptoms in the leucine-rich repeat kinase 2 (LRRK2(R1441G)) transgenic mouse. Neurosci Lett. 2013 Aug 9;549:57-62.

9. Dusonchet J, Kochubey O, Stafa K, Young SM, Zufferey R, Moore DJ, Schneider BL, Aebischer P. A rat model of progressive nigral neurodegeneration induced by the parkinson's disease-associated G2019S mutation in LRRK2. J Neurosci. 2011 Jan 19;31(3):907-12.

10. Emre M. What causes mental dysfunction in parkinson's disease? Mov Disord. 2003 Sep;18 Suppl 6:S63-71.

11. Fleming SM. Behavioral outcome measures for the assessment of sensorimotor function in animal models of movement disorders. Int Rev Neurobiol. 2009;89:57-65.

12. Fleming SM, Schallert T, Ciucci MR. Cranial and related sensorimotor impairments in rodent models of parkinson's disease. Behav Brain Res. 2012 Jun 1;231(2):317-22.

13. Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, Brice A, Aasly J, Zabetian CP, Goldwurm S, Ferreira JJ, Tolosa E, Kay DM, Klein C, Williams DR, Marras C, Lang AE, Wszolek ZK, Berciano J, Schapira AH, Lynch T, Bhatia KP, Gasser T, Lees AJ, Wood NW, International LRRK2 Consortium. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated parkinson's disease: A case-control study. Lancet Neurol. 2008 Jul;7(7):583-90.

14. Hutson CB, Lazo CR, Mortazavi F, Giza CC, Hovda D, Chesselet MF. Traumatic brain injury in adult rats causes progressive nigrostriatal dopaminergic cell loss and enhanced vulnerability to the pesticide paraquat. J Neurotrauma. 2011 Sep;28(9):1783-801.

15. Landers MR, Kinney JW, van Breukelen F. Forced exercise before or after induction of 6-OHDA-mediated nigrostriatal insult does not mitigate behavioral asymmetry in a hemiparkinsonian rat model. Brain Res. 2014 Jan 16;1543:263-70.

16. Lee BD, Shin J, VanKampen J, Petrucelli L, West AB, Ko HS, Lee Y, Maguire-Zeiss KA, Bowers WJ, Federoff HJ, Dawson VL, Dawson TM. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat. Med. (2010) 16, 998–1000.

17. Li X, Patel JC, Wang J, Avshalumov MV, Nicholson C, Buxbaum JD, Elder GA, Rice ME, Yue Z. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial parkinson's disease mutation G2019S. J Neurosci. 2010 Feb 3;30(5):1788-97.

18. Li Y, Liu W, Oo TF, Wang L, Tang Y, Jackson-Lewis V, Zhou C, Geggman K, Bogdanov M, Przedborski S, Beal MF, Burke RE, Li C. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of parkinson's disease. Nat Neurosci. 2009 Jul;12(7):826-8.

19. Matsumoto H, Noro H, Kaneshige Y, Chiba S, Miyano N, Motoi Y, Yanada Y. A correlation study between blink reflex habituation and clinical state in patients with parkinson's disease. J Neurol Sci. 1992 Feb;107(2):155-9.
20. Melrose HL, Dächsel JC, Behrouz B, Lincoln SJ, Yue M, Hinkle KM, Kent CB, Korvatska E, Taylor JP, Witten L, Liang YQ, Beevers JE, Boules M, Dugger BN, Serna VA, Gaukman A, Yu X, Castanedes-Casey M, Braithwaite AT, Ogholikhan S, Yu N, Bass D, Tyndall G, Schellenberg GD, Dickson DW, Janus C, Farrer MJ. Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol Dis. 2010 Dec;40(3):503-17.

21. Miyoshi E, Wietzikoski S, Camplessei M, Silveira R, Takahashi RN, Da Cunha C. Impaired learning in a spatial working memory version and in a cued version of the water maze in rats with MPTP-induced mesencephalic dopaminergic lesions. Brain Res Bull. 2002 May;58(1):41-7.

22. Olsson M, Nikkhah G, Bentlage C, Bjorklund A. Forelimb akinesia in the rat parkinson model: Differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci. 1995 May;15(5 Pt 2):3863-75.

23. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, López de Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Marti-Massó JF, Pérez-Tur J, Wood NW, Singleton AB. Cloning of the gene containing mutations that cause PARK8-linked parkinson's disease. Neuron. 2004 Nov 18;44(4):595-600.

24. Quinn R. Comparing rat's to human's age: How old is my rat in people years? Nutrition. 2005 Jun;21(6):775-7.

25. Ramonet D, Daher JP, Lin BM, Stafa K, Kim J, Banerjee R, Westerlund M, Pletnikova O, Glauser L, Yang L, Liu Y, Swing DA, Beal MF, Troncoso JC, McCaffery JM, Jenkins NA, Copeland NG, Galter D, Thomas B, Lee MK, Dawson TM, Dawson VL, Moore DJ. Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One. 2011 Apr 6;6(4):e18568.

26. Ruiz-Martinez J, de la Riva P, Rodriguez-Oroz MC, Mondragon Rezola E, Bergareche A, Gorostidi A, Gago B, Estanga A, Larrañaga N, Sarasqueta C, López de Munain A, Martí Massó JF. Prevalence of cancer in parkinson's disease related to R1441G and G2019S mutations in LRRK2. Mov Disord. 2014 May;29(6):750-5.

27. Santpere G, Ferrer I. LRRK2 and neurodegeneration. Acta Neuropathol. 2009 Mar;117(3):227-46.

28. Sulzer D. Multiple hit hypotheses for dopamine neuron loss in parkinson's disease. Trends Neurosci. 2007 5;30(5):244-50.

29. Tong Y, Pisani A, Martella G, Karouani M, Yamaguchi H, Pothis EN, Shen J. R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc Natl Acad Sci U S A. 2009 Aug 25;106(34):14622-7.

30. Tsika E, Moore DJ. Mechanisms of LRRK2-mediated neurodegeneration. Curr Neurol Neurosci Rep. 2012 Jun;12(3):251-60.

31. Tsika E, Moore DJ. Contribution of GTPase activity to LRRK2-associated Parkinson’s disease. Small GTPases. 2013 Jul-Sep;4(3):164-70.

32. Tsika E, Kannan M, Foo CS, Dikeman D, Glauser L, GellhaarS, Galter D, Knott GW, Dawson TM, Dawson VL, Moore DJ. Conditional expression of Parkinson's disease-related R1441C
LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration. Neurobiol Dis. 2014: Nov; 71:345-58.

33. Typlt M, Mirkowski M, Azzopardi E, Ruettiger L, Ruth P, Schmid S. Mice with deficient BK channel function show impaired prepulse inhibition and spatial learning, but normal working and spatial reference memory. PLoS One. 2013 Nov 26;8(11):e81270.

34. Valsamis B, Schmid S (2011) Habituation and prepulse inhibition of the acoustic startle in rodents. J Vis Exp (55):e3446.

35. Woodlee MT, Asseo-Garcia AM, Zhao X, Liu SJ, Jones TA, Schallert T. Testing forelimb placing "across the midline" reveals distinct, lesion-dependent patterns of recovery in rats. Exp Neurol. 2005 Feb;191(2):310-7.

36. Zhou H, Huang C, Tong J, Hong WC, Liu YJ, Xia XG. Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake. Int J Biol Sci. 2011;7(6):753-61.

37. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vierregge P, Asmus F, Müller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004 Nov 18;44(4):601-7.

38. Zoetmulder M, Biernat HB, Nikolic M, Korbo L, Friberg L, Jennum PJ. Prepulse inhibition is associated with attention, processing speed, and 123I-FP-CIT SPECT in parkinson's disease. J Parkinsons Dis. 2014;4(1):77-87.
Motor Testing

A) Vibrissae evoked forelimb placing was measured in transgenic $LRRK2^{R1441G}$ rats and wild-type littermates. While there was a significant influence of age group, there was no significant difference in forelimb placing between wild-type and transgenic $LRRK2^{R1441G}$ rats at 3, 6, 9, and 12 months of age. B) Performance in the adjusting steps task revealed also no significant differences in the number of adjusting steps between transgenic $LRRK2^{R1441G}$ rats and wild-type littermates at 3, 6, 9, and 12 months of age, while there was a significant of age group. C) Stride length was measured for each side (L indicates left side and R indicates right side) in each animal and averaged within genotype. Stride length increased significantly with age, but there was no significant difference in stride length in transgenic $LRRK2^{R1441G}$ rats and wildtype littermates at 3, 6, 9, and 12 month of age. D) Total distance travelled during a 30 min. session in the locomotor box. While there was again a significant influence of age group, there was no significant difference in total distance travelled between transgenic $LRRK2^{R1441G}$ rats and wild-type littermates. E) Rearing movements made by all animals was counted during testing sessions in the locomotor boxes. There was a significant decrease of rearing as animals aged, however, no significant difference was noted between transgenic $LRRK2^{R1441G}$ rats and wild-type littermates. F) Maximal velocity of transgenic and wild-type rats was calculated across testing sessions. No significant difference in maximal velocity was noted between transgenic $LRRK2^{R1441G}$ rats and wildtype littermates. N=24 transgenic and n=17 wild-type animals in all age groups.
**Figure 2** (on next page)

Sensorimotor Gating

A) Habituation scores were calculated for each rat by dividing the average of the last five startle responses by the maximum of the first three startle responses and then averaged across genotype. Habituation scores did not differ between transgenic LRRK2<sup>R1441G</sup> rats and wild-type littermates at 3, 6, 9, or 12 months of age. B) Mean habituation curves for the age of 3 and 12 months. Both wild-type and transgenic rats showed a significant decrease of startle response amplitudes over 30 trials with no significant difference between genotypes. C) Prepulse inhibition of startle in with a 75 dB and a 85 dB prepulse in 3 months (top) and 12 months (bottom) old rats. The remaining startle amplitude in relation to the baseline startle without any prepulse is plotted. There are no significant differences between genotypes or between age groups. N=24 transgenic and n=17 wild-type animals in all age groups.
**A. Habituation Scores**

- **Habituation Score**
  - **Age (months):** 3, 6, 9, 12
  - **WT** and **LRRK2**

**B. Short-Term Habituation**

- **3 months**
  - Startle Amplitude vs. Trial
  - **Baseline, 10, 30, 100 Interstimulus Interval**

- **12 months**
  - Startle Amplitude vs. Trial
  - **Baseline, 10, 30, 100 Interstimulus Interval**

**C. Prepulse Inhibition**

- **3 months - 75 dB**
  - Startle Amplitude vs. Interstimulus Interval

- **3 months - 85 dB**
  - Startle Amplitude vs. Interstimulus Interval

- **12 months - 75 dB**
  - Startle Amplitude vs. Interstimulus Interval

- **12 months - 85 dB**
  - Startle Amplitude vs. Interstimulus Interval
Morris Water Maze

A) Latency to find the target platform was measured across two training days in the cued version of the Morris water maze task. Performance on this task improved from training day 1 to training day 2 in 9 month old rats (left) and 12 months old rats (right), however, there was no significant difference between transgenic LRRK2^{R1441G} rats. B) Spatial learning in the Morris Water maze task. The average latency until finding the platform of four trials per day is plotted for four consecutive training days at 9 months of age (left) and 12 months of age (right). Both genotypes show similar learning curves. C) The first four trials of the first spatial reference training day in the Morris Water maze were analyzed separately to test for differences in working memory at 9 months (left) and 12 months (right) of age. There was no significant difference between genotypes. D) On a final probe day, the platform was removed and the amount of time spent in the target quadrant was assessed for 9 months (left) and 12 months (right) old animals. Again, there was no significant difference between the genotypes. N=24 transgenic and n=17 wild-type animals in all age groups.
Vulnerability to Paraquat

Rearing behavior following acute Paraquat or saline exposure was measured in \textit{LRRK2}^{R1441G} and wild-type rats. All animals were tested immediately after a first injection (injection 1), 24 hours after injection 1, immediately after injection 2, 24 hours after injection 2, and ten days after the last injection. There was a reduction in rearing movements in the Paraquat-exposed groups immediately after injections 1 and 2, but no significant difference in drug reactions between genotypes. Ten days following injections, there was no more drug effect on rearing behavior in any genotype. \( N = 8 \) wt xPQ, \( n = 10 \) LrrK2 x PQ, \( n = 8 \) wt x saline, \( n = 10 \) wt x PQ (one LrrK2 animal that died within this testing period was eliminated from this data).
Number of Rearing Movements

- Wt x PQ
- Wt x Saline
- Lrrk2 x PQ
- Lrrk2 x Saline

Locomotion

- Immediately after injection 1
- 24 h post injection 1
- Immediately after injection 2
- 24 h post injection 2
- Ten days post injections
Figure 5 (on next page)

Survival Curve

Survival rates were plotted for LRRK2<sup>R1441G</sup> (M=17.91, SEM=0.38) and WT rats (M=18.75, SEM=0.17). A log rank (Mantel-Cox) test revealed no significant differences in survival between transgenic and wild-type animals.
Survival Probability

Age (months)

Survival Probability

WT

LRRK2

0

0.2

0.4

0.6

0.8

1

1.2

1

3

5

7

9

11

13

15

17

PeerJ reviewing PDF | (2015:01:3864:1:1:NEW 16 Apr 2015)
Reviewing Manuscript
Figure 6 (on next page)

Substantia Nigra Histology

A) Tyrosine hydroxylase immunostaining of the substantia nigra in brain slices of 3, 6, and 18 months old rats. Slices were counterstained with Nissl staining. B) Hoechst 33342 stained sections of 3, 6, and 18 month old rats show cell nuclei in the substantia nigra. There are no pyknotic or fragmented cell nuclei that would indicate a higher rate of apoptotic cell death in old or transgenic animals. C) Quantification of DAB stained area of three sections per animal. Tyrosine hydroxylase immunostained area was not significantly different between genotypes. D) The number of cell nuclei within a defined window does not differ between age stages, indicating that the total number of cells does not considerably change despite the smaller area of DAB staining in older animals. Error bars refer to standard deviation between three brain section analysed per brain by two different scorers each.
Figure 7 (on next page)

Striatum Histology

A) Dopamine transporter (DAT) immunoreactivity in the striatum of 3 and 9 month old wt and LRRK2\textsuperscript{R1441G} rats. The squares indicate the regions that were quantitatively analyzed. B) Quantitative analysis of DAT staining in the striatum revealed a significant reduction of DAT expression in older animals, but no difference between genotypes. C) Expression of tyrosine hydroxylase (TH) in the striatum of the same rats. D) Quantitative analysis of TH expression revealed no difference between age groups and genotypes. Error bars refer to standard deviation between three brain section analysed per brain by two different scorers each.
Table 1 (on next page)

qRT-PCR

Relative expression of the human \( LRRK2^{R1441G} \) RNA in the substantia nigra of transgenic animals. A wild-type sample served as negative control and a sample of a \( LRRK2^{G2019S} \) rat as positive control. Expression was normalized to the expression of the housekeeping gene GAPDH.
| Animal ID | Genotype  | DOB       | Tissue       | LRRK2 expression | GAPDH expression |
|-----------|-----------|-----------|--------------|------------------|------------------|
|           |           |           | Mean         | SD               | Mean             | SD               |
| 101       |           | 7/26/2012 | Hippocampus  | -                | 17.808           | 0.203            |
|           |           |           | Substantia Nigra | -                | 18.217           | 0.287            |
|           |           |           | Cortex       | -                | 21.133           | 0.212            |
|           |           |           | Kidney       | -                | 19.127           | 0.142            |
|           |           |           | Liver        | -                | 18.912           | 0.096            |
| 102       |           | 7/26/2012 | Hippocampus  | -                | 18.730           | 0.169            |
|           |           |           | Substantia Nigra | -                | 19.639           | 0.025            |
|           |           |           | Cortex       | -                | 17.477           | 0.581            |
|           |           |           | Kidney       | -                | 18.105           | 0.372            |
|           |           |           | Liver        | -                | 18.790           | 0.161            |
| 104       |           | 7/26/2012 | Hippocampus  | -                | 18.897           | 0.928            |
|           |           |           | Substantia Nigra | -                | 21.802           | 4.886            |
|           |           |           | Cortex       | -                | 19.578           | 0.121            |
|           |           |           | Kidney       | -                | 19.308           | 0.360            |
|           |           |           | Liver        | -                | 22.004           | 0.194            |
| 303       |           | 8/5/2012  | Hippocampus  | -                | 20.458           | 0.347            |
|           |           |           | Substantia Nigra | -                | 20.347           | 0.961            |
|           |           |           | Cortex       | -                | 19.271           | 0.261            |
|           |           |           | Kidney       | -                | 18.998           | 1.423            |
|           |           |           | Liver        | -                | 21.391           | 0.311            |
| 305       |           | 8/5/2012  | Hippocampus  | -                | 19.391           | 0.287            |
|           |           |           | Substantia Nigra | -                | 20.340           | 1.455            |
|           |           |           | Cortex       | -                | 19.271           | 0.261            |
|           |           |           | Kidney       | -                | 18.901           | 0.102            |
|           |           |           | Liver        | -                | 21.164           | 0.351            |
| 404       |           | 9/16/2012 | Hippocampus  | -                | 19.710           | 0.153            |
|           |           |           | Substantia Nigra | -                | 20.246           | 0.051            |
|           |           |           | Cortex       | -                | 19.144           | 0.567            |
|           |           |           | Kidney       | -                | 20.316           | 0.669            |
|           |           |           | Liver        | -                | 23.021           | 3.470            |
| 406       |           | 9/16/2012 | Hippocampus  | -                | 21.827           | 5.225            |
|           |           |           | Substantia Nigra | -                | 20.121           | 0.083            |
|           |           |           | Cortex       | -                | 18.711           | 0.251            |
|           |           |           | Kidney       | -                | 19.768           | 0.282            |
|           |           |           | Liver        | -                | 22.133           | 0.081            |
| 502       |           | 9/25/2012 | Hippocampus  | -                | 18.933           | 0.103            |
|           |           |           | Substantia Nigra | -                | 20.223           | 0.550            |
|           |           |           | Cortex       | -                | 20.541           | 0.069            |
| Tissue          | Date     | Protein 1  | Protein 2  | Protein 3  |
|-----------------|----------|------------|------------|------------|
| Kidney          | -        | 19.134     | 0.029      |            |
| Liver           | -        | 21.181     | 0.335      |            |
| 503             | 9/25/2012| Hippocampus| 23.215     | 0.079      |
| Substantia Nigra| -        | 24.910     | 0.151      |            |
| Cortex          | -        | 23.557     | 0.258      |            |
| Kidney          | -        | 25.013     | 3.874      |            |
| Liver           | -        | 20.843     | 0.110      |            |
| 506             | 9/25/2012| Hippocampus| 18.746     | 0.283      |
| Substantia Nigra| -        | 18.474     | 0.085      |            |
| Cortex          | -        | 21.564     | 0.106      |            |
| Kidney          | -        | 28.604     | 0.233      |            |
| Liver           | -        | 21.927     | 0.899      |            |
| 703             | 9/29/2012| Hippocampus| 21.522     | 0.130      |
| Substantia Nigra| -        | 34.326     | 0.436      |            |
| Cortex          | -        | 21.379     | 0.127      |            |
| Kidney          | -        | 26.567     | 0.194      |            |
| Liver           | -        | 23.392     | 0.092      |            |
| Pos. C          | n/a      | Human tissue| 15.452     | 0.324      |
|                 |          |            | 21.522     | 0.130      |